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Renal transplant recipients are often anemic in the early
post-engraftment period because of preexisting anemia
exacerbated by perioperative blood loss [1]. Six or more
months after transplantation, anemia is slightly less com-
mon, and mostly occurs in the setting of chronic allograft
nephropathy associated with reduced glomerular filtration
rate [1]. We report the first pediatric case of anemia after
renal transplantation caused by the use of irbesartan, a drug
that inhibits the renin-angiotensin II-aldosterone system by
blocking the type 1 of angiotensin II receptors [2–5].
A 12-year-old boy with a history of congenital nephrotic
syndrome of the Finnish type and poor renal function (GFR
estimated 25 ml/min/1.73 m2, urinary protein/creatinine
ratio 48 mg/mmol) 7 years after a cadaveric transplantation
was on treatment with the immunosuppressants mycophe-
nolate and sirolimus. This rather unusual immunosuppres-
sive regimen had been started 2 years earlier because of
resistant arterial hypertension and chronic nephropathy
while on therapy with cyclosporine A, azathioprine and
prednisone. The chronic antihypertensive regimen included
the calcium-channel blocker amlodipine (0.16 mg/kg body
weight once a day), the β-blocker metoprolol (1.7 mg/kg
body weight once a day) and irbesartan (up to 10 mg/kg
body weight once a day). An important hyporegenerative
normocytic anemia (hemoglobin 63 g/l) was noted, which
was not associated with either acute or chronic infections,
including testing for Parvovirus B19 infection, and failed to
improve on parenteral iron and recombinant human
erythropoietin (at the beginning 170 IU/kg weekly,
increased during anemia up to 230 IU/kg weekly). Finally,
hemoglobin increased up to 119 g/l within 4 weeks after
withdrawing irbesartan (Fig. 1).
Drugs that inhibit the renin-angiotensin II-aldosterone
system modestly decrease hemoglobin and circulating
erythropoietin [1]. Like converting enzyme inhibitors,
angiotensin II receptors blockers may produce anemia
either by direct inhibition of erythropoietin or insulin-like
growth factor-1 production, or via an indirect mechanism
that improves renal perfusion and subsequently decreases
oxygen consumption. Furthermore, a negative effect on
hematopoiesis at the bone-marrow level has also been
suggested, since angiotensin II type 1 receptors have been
identified on erythroid progenitors [6].
The effect on hemoglobin is usually of limited clinical
relevance, and should not stand in the way of use of these
agents for their cardioprotective and renoprotective effects
[1, 2]. The present report confirms that there may be
“susceptible” patients for whom hemoglobin levels de-
crease significantly on drugs that inhibit the renin-angio-
tensin II-aldosterone system [1]. Thus, in selected cases,
some thought could be given to engineering a “drug
holiday” to test whether hemoglobin level increases after
discontinuation, as previously reported in a child with
nephrotic syndrome on treatment with the converting
enzyme inhibitor enalapril [7].
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Fig. 1 Hemoglobin levels with and without irbesartan, a drug that
inhibits the renin-angiotensin II-aldosterone system by blocking the
type 1 of angiotensin II receptors
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